EMV Capital PLC
LLSE:EMVC42.50
GBX
-3.00
(-6.59%)
ISIN
GB00BN4R5Q82
Return %
Stock
S&P 500
1Y
-5.56
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Ilian Petkov Iliev
- Full Time Employees
- 21
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 2nd Floor London GL United Kingdom W1S 3AN
- IPO Date
- Sep 16, 2013
- Website
- emvcapital.com
- Similar Companies
- Business
- EMV Capital plc is a United Kingdom-based deep tech and life sciences venture capital investment group focused on identifying, investing in, managing, and strengthening early-stage companies with high-growth potential and attractive intellectual property. The company operates internationally with a portfolio of over 70 companies across sectors including life sciences, industrial technology, robotics, artificial intelligence, and sustainability. Its core products and services include venture capital funding, portfolio management, value creation services such as investment readiness and exit readiness support, intellectual property strategy, corporate collaborations, and senior executive placements. EMV Capital employs a capital-efficient investment strategy using its balance sheet and syndicated investments to acquire both direct equity stakes and carried interest in its portfolio companies. The company supports portfolio companies from early stages through to successful exits via M&A, IPOs, or sales to private equity and other financial investors. Recent major changes include the consolidation of Martlet Capital into its operations, expanding its assets under management to over £100 million and its portfolio to more than 70 companies. In 2025, EMV Capital successfully launched a Fund Management practice to complement its venture building activities and completed a £1.5 million placing at a 15% premium to market price. Its wholly owned subsidiary Moirai Acquisitions Limited acquired assets related to Destiny Pharma's XF-73 drug platform, a novel antibiotic with advantages over traditional treatments, further expanding its life sciences portfolio. The company also appointed a new group chief financial officer and created a separate portfolio CFO role to support its growing asset base and diverse revenue streams. Founded in 2008 and headquartered in London, EMV Capital continues to focus on generating superior returns by proactively managing its portfolio companies and driving their advancement to critical value inflection points through its operational expertise and strategic partnerships.